Akero Therapeutics, Inc. (AKRO): Price and Financial Metrics


Akero Therapeutics, Inc. (AKRO): $39.26

0.95 (+2.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AKRO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AKRO Stock Price Chart Interactive Chart >

Price chart for AKRO

AKRO Price/Volume Stats

Current price $39.26 52-week high $39.74
Prev. close $38.31 52-week low $7.52
Day low $38.04 Volume 669,398
Day high $39.74 Avg. volume 654,192
50-day MA $18.63 Dividend yield N/A
200-day MA $15.16 Market Cap 1.48B

Akero Therapeutics, Inc. (AKRO) Company Bio


Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.


AKRO Latest News Stream


Event/Time News Detail
Loading, please wait...

AKRO Latest Social Stream


Loading social stream, please wait...

View Full AKRO Social Stream

Latest AKRO News From Around the Web

Below are the latest news stories about AKERO THERAPEUTICS INC that investors may wish to consider to help them evaluate AKRO as an investment opportunity.

Purple Innovation and Edgewise Therapeutics Stock See Action From Activist Investors

Coliseum Capital acquired almost half of the publicly traded shares of mattress firm Purple. OrbiMed Advisors increased its stake in pharmaceutical firm Edgewise Therapeutics.

Yahoo | September 23, 2022

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced upsized underwritten public offering of 8,846,154 shares of its common stock at a public offering price of $26.00 per share, which includes the exercise in full by the underwriters of their option

Yahoo | September 19, 2022

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 7,692,308 shares of its common stock at a public offering price of $26.00 per share. All of the shares in the offering are being offered by Akero Therapeutics. In addition, Akero

Yahoo | September 15, 2022

Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More

Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.

Yahoo | September 14, 2022

Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90

Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. The biotech stock is extended and is not currently near a potential buy zone.

Yahoo | September 14, 2022

Read More 'AKRO' Stories Here

AKRO Price Returns

1-mo 193.86%
3-mo 243.48%
6-mo 183.06%
1-year 81.59%
3-year 112.79%
5-year N/A
YTD 85.63%
2021 -18.02%
2020 16.24%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4577 seconds.